Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - metforminhydroklorid; vildagliptin - filmdragerad tablett - 50 mg/850 mg - laktosmonohydrat hjälpämne; metforminhydroklorid 850 mg aktiv substans; vildagliptin 50 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - metforminhydroklorid; vildagliptin - filmdragerad tablett - 50 mg/1000 mg - laktosmonohydrat hjälpämne; vildagliptin 50 mg aktiv substans; metforminhydroklorid 1000 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medochemie ltd - vildagliptin - tablett - 50 mg - vildagliptin 50 mg aktiv substans; laktos (vattenfri) hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - vildagliptin - tablett - 50 mg - vildagliptin 50 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - vildagliptin - tablett - 50 mg - laktosmonohydrat hjälpämne; vildagliptin 50 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - metforminhydroklorid; vildagliptin - filmdragerad tablett - 50 mg/850 mg - vildagliptin 50 mg aktiv substans; propylenglykol hjälpämne; mannitol hjälpämne; metforminhydroklorid 850 mg aktiv substans